ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 774

Citrullination Of ENA-78/CXCL5 Changes Its Receptor Affinity From CXCR2 To CXCR1 and Induces Monocyte Migration

Ken Yoshida1, Alisa E. Koch1,2, Ray A. Ohara3, Phillip L. Campbell1, M. Asif Amin1, David A. Fox1 and Jeffrey H. Ruth4, 1Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 2VA Medical Service, Ann Arbor, MI, 3University of Michigan Medical School, Ann Arbor, MI, 4Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Chemokine Receptors, chemokines, citrullination, monocytes and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I: Identifying Novel Factors that Facilitate Neovascularization and Cell Trafficking

Session Type: Abstract Submissions (ACR)

Background/Purpose: We previously showed that citrullinated epithelial-derived neutrophil-activating peptide 78/CXCL5 (citENA-78/CXCL5) was significantly higher in rheumatoid arthritis (RA) synovial fluids (SFs) compared to osteoarthritis (OA) and other inflammatory rheumatic diseases (OD) SFs, and its concentration correlates with RA disease activity. Furthermore, we have shown that citrullination of ENA-78/CXCL5 results in conversion from a non-monocyte recruiting to a monocyte recruiting chemokine. We now examine the cellular receptors utilized by citENA-78/CXCL5 to induce monocyte migration in vitro.

Methods: Citrullination of ENA-78/CXCL5 was verified by mass spectrometry and Western blot analysis with anti-modified citrulline antibody (AMC). We initially performed polymorphonuclear neutrophil(PMN) chemotaxis assays to citENA-78/CXCL5 using a 48-well Boyden chamber system to determine if citrullination altered recruitment activity of ENA-78/CXCL5 for PMNs. Next, we performed monocyte chemotaxis assays to determine whether citENA-78/CXCL5 induced monocyte chemotaxis. Finally, we investigated whether cell recruitment could be inhibited by pertussis toxin (PTX), which is a G protein-coupled receptor antagonist, or with anti-CXCR1 and/or anti-CXCR2 blocking antibodies. For in vivo analysis, C57BL/6 mice were injected intra-articularly (i.a.) with non-cit or citENA-78/CXCL5 to induce inflammation. Immunofluorescence (IF) staining was performed on injected joint tissues using anti-F4/80 antibody, which is specific for monocytes/macrophages, to determine the number of recruited monocytes/macrophages to mouse joints.

Results: citENA-78/CXCL5 was recognized by AMC, while non-citENA-78/CXCL5 was not. Chemotaxis assays showed that citENA-78/CXCL5 induced less PMN migration compared to non-citENA-78/CXCL5, indicating that the binding affinity for PMN chemokine receptors was altered by citrullination of ENA-78/CXCL5. Monocyte chemotaxis assays showed that citrullinated ENA-78/CXCL5 significantly enhanced monocyte migration, while non-citENA-78/CXCL5 did not. PTX completely inhibited citENA-78/CXCL5-induced monocyte chemotaxis, indicating that citENA-78/CXCL5 is binding to a G-protein coupled receptor. Anti-CXCR1 and 2 antibodies both partially reduced the monocyte chemotaxis, and a combination of anti-CXCR1 and 2 antibodies completely inhibited monocyte chemotaxis. Lastly, IF staining showed that citENA-78/CXCL5 recruited more F4/80 positive monocytes/macrophages into mouse knee joints compared to non-citENA-78/CXCL5.

Conclusion: Our results show that citENA-78 induces monocyte migration via CXCR1 and CXCR2, and indicate that citrullination may increase the affinity of ENA-78/CXCL5 for CXCR1. Our data also shows that citENA-78/CXCL5 is a potent recruitment factor for monocytes, but a poor recruitment factor for PMNs. citENA-78/CXCL5 also induced more macrophage accumulation in synovium when injected into mouse knee joints compared to non-citENA-78/CXCL5. These results show that citrullination of ENA-78/CXCL5 can alter its receptor affinity and cellular recruitment properties.


Disclosure:

K. Yoshida,
None;

A. E. Koch,

Eli Lilly and Company: I am currently employed by Eli Lilly with an adjunct appointment at University of Michigan. My work at Lilly is not relevant to the content of the abstract.,

3;

R. A. Ohara,
None;

P. L. Campbell,
None;

M. A. Amin,
None;

D. A. Fox,
None;

J. H. Ruth,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/citrullination-of-ena-78cxcl5-changes-its-receptor-affinity-from-cxcr2-to-cxcr1-and-induces-monocyte-migration/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology